首页 > 市场调查报告书 > 製药

再生医学细胞疗法

细胞和基因治疗市场规模、份额和成长分析（按治疗方法、治疗领域、最终用户和地区划分）—2026-2033年产业预测

市场调查报告书

商品编码

1899701

细胞和基因治疗市场规模、份额和成长分析（按治疗方法、治疗领域、最终用户和地区划分）—2026-2033年产业预测

Cell and Gene Therapy Market Size, Share, and Growth Analysis, By Therapy Type (Cell Therapy, Gene Therapy), By Therapeutic Class (Cardiovascular Disease, Rare Diseases), By End Users, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 194 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球细胞和基因治疗市场规模预计在 2024 年达到 294.4 亿美元，从 2025 年的 348.8 亿美元增长到 2033 年的 1356.2 亿美元，在预测期（2026-2033 年）内复合年增长率为 18.5%。

全球细胞和基因治疗市场的成长主要受慢性疾病（例如癌症和罕见遗传疾病）的日益增多所驱动，这些疾病难以透过传统治疗方法有效治疗。这项持续存在的医疗挑战促使医疗专业人员和製药公司寻求能够提供标靶、个人化治疗的创新治疗方法。筛检技术的进步和人口老化导致确诊患者数量不断增加，进一步推动了对这些治疗方法的需求，从而增加了投资和临床试验。生物技术领域的突破性进展，特别是基因编辑技术（例如 CRISPR-Cas9），正在提高治疗的精准性和患者安全性，并促进监管部门的核准。这些进步不仅加速了研发进程，也吸引了更多投资，并扩大了市场上新型治疗方法方案的数量。

全球细胞和基因治疗市场按治疗方法类型、治疗疾病、最终用户和地区进行细分。依治疗方法类型划分，市场分为细胞治疗和基因治疗两大类。依治疗疾病划分，市场分为心血管疾病、癌症、遗传性疾病、罕见疾病、肿瘤、血液疾病、眼科疾病、感染疾病、神经系统疾病及其他疾病。依最终用户划分，市场分为医院、癌症治疗中心等机构。依地区划分，市场分为北美、欧洲、亚太、拉丁美洲以及中东和非洲。

全球细胞和基因治疗市场驱动因素

遗传性疾病和罕见疾病的日益普遍正显着地推动细胞和基因治疗市场的发展。这些先进治疗方法为曾经被认为无法治癒的疾病提供了根治性方案，引起了患者和医疗服务提供者的极大关注。不断增长的患者需求和诊断技术的进步推动了对创新和标靶治疗方法的需求。这一趋势正在促进突破性治疗方法的研发和投资，以应对复杂的健康挑战，从而为全球细胞和基因疗法市场创造了良好的发展环境。因此，该市场正经历着巨大的成长和扩张机会。

限制全球细胞和基因治疗市场的因素

全球细胞和基因治疗市场面临许多限制因素，例如开发这些治疗方法需要大量的临床前研究、复杂的临床试验以及严格的监管核准流程。产品上市週期过长不仅会延缓其上市时间，还会增加研发成本。对于中小企业而言，这项挑战尤其突出，因为它们往往难以应对漫长的投资週期。因此，创新可能会受到抑制，最终影响新治疗方法进入全球市场的速度，并限制患者治疗方案的进展。

全球细胞和基因治疗市场趋势

全球细胞和基因治疗市场正经历一场变革，而这主要得益于个人化医疗的兴起。个人化医疗能够根据患者独特的基因谱量身定制治疗方案，从而提高疗效并最大限度地减少有害副作用，尤其适用于治疗罕见疾病和复杂疾病。随着医疗保健越来越注重以患者为中心的解决方案，利用基因资讯进行创新治疗方法的需求也随之飙升。这一趋势不仅加速了市场成长，也促进了研究人员、医疗服务提供者和生技公司之间的合作，最终将为全球带来更有效的治疗方法和更好的患者疗效。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Novartis（Switzerland）
Gilead Sciences（USA）
Bristol Myers Squibb（USA）
bluebird bio（USA）
Kite Pharma（USA）
Sangamo Therapeutics（USA）
Moderna（USA）
Editas Medicine（USA）
Cellectis（France）
Orchard Therapeutics（UK）
UniQure（Netherlands）
Regenxbio（USA）
Spark Therapeutics（USA）
Fosun Pharma（China）
MeiraGTx（UK）

结论与建议

简介目录

Product Code: SQMIG35D2325

Global Cell & Gene Therapy Market size was valued at USD 29.44 Billion in 2024 and is poised to grow from USD 34.88 Billion in 2025 to USD 135.62 Billion by 2033, growing at a CAGR of 18.5% during the forecast period (2026-2033).

The global cell and gene therapy market is significantly propelled by the rising prevalence of chronic diseases, including cancer and rare genetic disorders, which often elude effective treatment from traditional modalities. This ongoing medical challenge drives healthcare professionals and pharmaceutical entities to pursue innovative therapies that provide targeted and personalized solutions. The growing pool of diagnosed patients, aided by advancements in screening and an aging demographic, further fuels demand for these therapies, resulting in increased investment and clinical trials. Breakthroughs in biotechnology, particularly with gene editing technologies like CRISPR-Cas9, enhance therapeutic precision and patient safety, facilitating regulatory approvals. These advancements not only accelerate research and development but also attract further investments, broadening the array of novel treatments in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell & Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell & Gene Therapy Market Segments Analysis

The global cell and gene therapy market is segmented based on therapy type, therapeutic class, end-users, and region. In terms of therapy type, the market is bifurcated into cell therapy and gene therapy. Based on therapeutic class, the market is segmented into cardiovascular disease, cancer, genetic disorder, rare diseases, oncology, hematology, ophthalmology, infectious disease, neurological disorders, and others. Based on end-users, the market is trifurcated into hospitals, cancer care centers, and others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Central & South America and the Middle East & Africa.

Driver of the Global Cell & Gene Therapy Market

The increasing prevalence of genetic disorders and rare diseases significantly propels the cell and gene therapy market. These advanced therapies provide curative solutions for ailments once thought to be untreatable, attracting considerable interest from both patients and healthcare providers. With heightened patient demand and advancements in diagnostic technologies, there is an escalating necessity for innovative and targeted treatment options. This trend fosters a robust environment for the global cell and gene therapy market, encouraging further development and investment in groundbreaking therapies aimed at tackling complex health challenges. As a result, the market is experiencing substantial growth and expansion opportunities.

Restraints in the Global Cell & Gene Therapy Market

The Global Cell and Gene Therapy market faces significant constraints due to the extensive preclinical research, intricate clinical trials, and stringent regulatory approval processes required for developing these therapies. The lengthy timeline for bringing products to market not only delays their availability but also escalates research and development costs. This challenge is particularly pronounced for smaller companies, which often find it difficult to manage prolonged investment cycles. As a result, innovation may be hindered, ultimately affecting the rate of new therapies entering the global market and limiting advancements in treatment options for patients.

Market Trends of the Global Cell & Gene Therapy Market

The global cell and gene therapy market is witnessing a transformative trend driven by the emergence of personalized medicine, which tailors treatments to the unique genetic profiles of patients. This individualized approach enhances therapeutic efficacy and minimizes adverse side effects, making it particularly beneficial for addressing rare and complex diseases. As healthcare becomes increasingly focused on patient-centric solutions, the demand for innovative therapies that harness genetic insights is surging. This trend not only accelerates market growth but also fosters a collaborative environment among researchers, healthcare providers, and biotechnology firms, ultimately leading to more effective treatments and better patient outcomes on a global scale.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Technology Assessment

Global Cell and Gene Therapy Market Size by Therapy Type & CAGR (2026-2033)

Market Overview
Cell Therapy
Gene Therapy

Global Cell and Gene Therapy Market Size by Modality & CAGR (2026-2033)

Market Overview
In Vivo
Ex Vivo

Global Cell and Gene Therapy Market Size by Indication & CAGR (2026-2033)

Market Overview
Oncology
Cardiovascular Diseases
Neurological Disorders
Musculoskeletal Disorders
Ophthalmic Disorders
Metabolic & Genetic Disorders
Infectious Diseases
Others

Global Cell and Gene Therapy Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals & Clinics
Academic & Research Institutes
Biopharmaceutical & Biotechnology Companies
Cell Therapy Centers
Others

Global Cell and Gene Therapy Market Size & CAGR (2026-2033)

North America (Therapy Type, Modality, Indication, End User)
- US
- Canada
Europe (Therapy Type, Modality, Indication, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Therapy Type, Modality, Indication, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Therapy Type, Modality, Indication, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Therapy Type, Modality, Indication, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Novartis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bluebird bio (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kite Pharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Editas Medicine (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cellectis (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orchard Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UniQure (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regenxbio (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Spark Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fosun Pharma (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MeiraGTx (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments